Figure 4.
Monitoring response to therapy with deep in situ immune phenotyping by mIHC
(A) Primary tumor (PT) and Bx1–Bx4 were subjected to multiplex immunohistochemistry (mIHC) analyses measuring immune (CD45+) and epithelial (PanCK+) cells in tumor compartments as a percentage of total nucleated cells.
(B) Representation of tissue composition, showing density (number of cells per square millimeter of tissue analyzed) of PanCK+ (cytokeratin), CD45+, and PanCK− CD45− (other) nucleated cells.
(C) Immune composition of seven major leukocyte lineages, as a percentage of total CD45+ cells.
(D) Deeper auditing of leukocyte lineages in Bx1 and Bx2, measuring 12 immune cell populations and functional states.
(E) CD3+ T cell proportions of total CD45+ cell populations (orange, left), and CD4+ (blue) and CD8+ T cells (periwinkle) proportions within CD45+CD3+ T cells (right).
(F) PD-1+ cells as a percentage of total CD3+T cells in the CD3+CD4+ (top) and CD3+CD8+ (bottom) T cell populations.
(G) Differentiation state of CD3+CD4+ T cells, reflected by regulatory T (Treg), Th1, and Th2, Th17, and Th0/γδ subsets (left) and CD3+CD8+ T cells, as reflected by expression of PD-1 and EOMES.
(H) Differentiation state of CD3+CD4+ T cells reflected by Treg, Th17, Th1, Th2, and Th0/γδ subsets in Bx1 and Bx2.